腦血管痙攣（CVS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 美國市場預計將從約 1.02 億美元成長到約 1.7 億美元（年複合成長率約 5-6%）。
• 先進的重症監護和血管內治療正在推動成長，而有針對性的藥物創新卻受到限制。

腦血管痙攣（CVS）概述

腦血管痙攣（CVS）是顱內動脈瘤破裂導致蜘蛛膜下腔出（aSAH）的嚴重且可能危及生命的併發症，其特徵是顱內主要動脈延遲性狹窄。它通常在出血後3至14天發生，是導致患者發病率和死亡率的主要因素。

此病的病理生理機轉是由蛛網膜下腔內紅血球的破壞引發的。這會導致氧合血紅素和其他致癇因子的釋放，進而導致一氧化氮耗竭、神經發炎、氧化壓力和血管重塑。這種連鎖反應可導致腦血流量減少，最終發展為遲發性腦缺血（DCI），而遲發性腦缺血是神經系統預後不良的主要決定因素。

臨床上，CVS表現為新發神經功能缺損、意識障礙及中風風險。診斷需密切監測，可採用經經顱都卜勒（TCD）和CT血管攝影檢查，其中數位減影血管攝影檢查（DSA）為黃金標準。

目前的標準治療方案強調維持正常血液容積和預防誘發性高血壓，以最佳化腦灌注。藥物治療方面，已證實具有神經保護作用的尼莫地平仍是核心治療藥物。對於難治性病例，可採用血管內治療，包括動脈內血管擴張劑和球囊血管成形術，以恢復腦血流。

主要亮點

• CVS 是 aSAH 的常見併發症，源自於延遲性缺血的風險。
• 預計美國蛛網膜下腔出血 (aSAH) 的發生率將從約 36,100 例增加到約 39,400 例（年複合成長率約為 0.9%）。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Idorsia

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
• 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Cerebral Vasospasm (CVS) Market Outlook

Thelansis's "Cerebral Vasospasm (CVS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cerebral Vasospasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cerebral Vasospasm (CVS) Overview

Cerebral vasospasm (CVS) is a severe and potentially life-threatening complication of aneurysmal subarachnoid hemorrhage (aSAH), characterized by delayed narrowing of major intracranial arteries. It typically occurs between 3 to 14 days post-hemorrhage and is a major contributor to morbidity and mortality in affected patients.

The pathophysiology is driven by the breakdown of erythrocytes in the subarachnoid space, releasing oxyhemoglobin and other spasmogenic factors, which lead to depletion of nitric oxide, neuroinflammation, oxidative stress, and vascular remodeling. This cascade results in reduced cerebral blood flow, potentially progressing to delayed cerebral ischemia (DCI), a key determinant of poor neurological outcomes.

Clinically, CVS presents with new-onset neurological deficits, altered consciousness, and risk of cerebral infarction. Diagnosis requires close monitoring using transcranial Doppler (TCD) and CT angiography, with digital subtraction angiography (DSA) as the gold standard.

The current standard of care emphasizes maintenance of euvolemia and induced hypertension to optimize cerebral perfusion. Pharmacologically, nimodipine remains the cornerstone therapy due to its proven neuroprotective benefits. In refractory cases, endovascular interventions, including intra-arterial vasodilators and balloon angioplasty, are employed to restore cerebral blood flow.

Key Highlights

• CVS is a high-morbidity complication of aSAH, driven by delayed ischemia risk
• US aSAH incidence expected to increase from ~36.1K to ~39.4K (~0.9% CAGR)

Market Overview

• US market projected to grow from ~$102M to ~$170M (~5-6% CAGR)
• Growth driven by advanced critical care and endovascular interventions, with limited targeted pharmacologic innovation

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Idorsia

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)